File(s) not publicly available

Reason: No Enhanced Content

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

online resource
posted on 13.02.2018 by Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G. Terra, James P. Mancuso, Samuel S. Engel, Brett Lauring

Article full text


The full text of this article can be found here.


Provide enhanced content for this article


There are currently no enhanced features for this article. If you are an author of this publication and would like to provide additional enhanced content for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.


Enhanced features include, but are not limited to:


· Summary slides

· Slide decks

· Videos and animations

· Audio abstracts

· Audio slides

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, in collaboration with Pfizer Inc.

History

Exports

Logo branding

Exports